Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response Hongshan LiJingyu YuYaning Wang Original Paper 01 June 2017 Pages: 403 - 414
Deterministic identifiability of population pharmacokinetic and pharmacokinetic–pharmacodynamic models Vijay K. SiripuramDaniel F. B. WrightStephen B. Duffull Original Paper 13 June 2017 Pages: 415 - 423
Challenges in longitudinal exposure-response modeling of data from complex study designs: a case study of modeling CDAI score for ustekinumab in patients with Crohn’s disease Chuanpu HuOmoniyi J. AdedokunHonghui Zhou Original Paper 16 June 2017 Pages: 425 - 436
Improvement in latent variable indirect response modeling of multiple categorical clinical endpoints: application to modeling of guselkumab treatment effects in psoriatic patients Chuanpu HuBruce RandazzoHonghui Zhou Original Paper 20 June 2017 Pages: 437 - 448
Integrated TK–TD modeling for drug-induced concurrent tachycardia and QT changes in beagle dogs Fan WuTycho HeimbachHandan He Original Paper 22 June 2017 Pages: 449 - 462
Target-mediated drug disposition model for drugs with two binding sites that bind to a target with one binding site Leonid GibianskyEkaterina Gibiansky Original Paper 19 July 2017 Pages: 463 - 475
Evaluation of pharmacokinetic model designs for subcutaneous infusion of insulin aspart Erin J. MansellSigne SchmidtHenrik Madsen Original Paper 22 August 2017 Pages: 477 - 489
Chemotherapeutic dosing implicated by pharmacodynamic modeling of in vitro cytotoxic data: a case study of paclitaxel Hua HeYanguang Cao Original Paper 31 August 2017 Pages: 491 - 501
Landmark and longitudinal exposure–response analyses in drug development Chuanpu HuHonghui ZhouAmarnath Sharma Commentary 20 July 2017 Pages: 503 - 507
